Best-practice articles for Regulatory Affairs, BE, and development teams working with comparator product and FDA-designated Reference Listed Drug (RLD) sourcing.
Explore short, regulator-aware briefings on terminology precision, study planning clarity, and sourcing fundamentals for ANDA and bioequivalence programs.
Explains why RLD batch selection matters in bioequivalence study planning, covering batch traceability, expiry windows, storage and handling, and single- vs multi-batch sourcing considerations.
Read full articleExplains when dissolution data may support a biowaiver of in-vivo bioequivalence studies, covering BCS-based waivers, additional-strength bridging evidence, and reference product considerations.
Read full articleClarifies whether a Comparative Dissolution Profile is required in an ANDA, how CDP differs from bioequivalence studies, and when dissolution data may receive greater regulatory attention.
Read full articleExplains how Comparative Dissolution Profile testing supports bioequivalence planning, f2 similarity assessment, BCS biowaiver evaluation, and why batch traceability matters for reference products.
Read full articleExplains how the RLD shifts from a physical comparator in BE study execution to a regulatory anchor in ANDA filings, and why alignment and traceability support defensible submissions.
Read full articleClarifies where comparator and RLD terms overlap, where they differ, and why terminology precision helps avoid regulatory ambiguity in multi-market development programs.
Read full articleA structured explainer on how the FDA-designated RLD anchors pharmaceutical equivalence, comparator selection, and documentation consistency across development and submission stages.
Read full articleShare your target submission market, required timeline, and storage condition needs for an availability response aligned with regulated development use.
Request a Quote